Telavancin

• Published in: Drugs (New York, N.Y.) N.Y.), 2009-01, Vol.69 (18), p.2607-2620
• Main Authors: Lyseng-Williamson, Katherine A., Blick, Stephanie K. A.
• Format: Article
• Language: English
• Subjects: Adis Drug Profile; Adult; Aminoglycosides - administration & dosage; Aminoglycosides - adverse effects; Aminoglycosides - therapeutic use; Animals; Anti-Bacterial Agents - adverse effects; Antibacterial agents; Antibiotics. Antiinfectious agents. Antiparasitic agents; Bacteria; Bacterial diseases; Biological and medical sciences; Clinical trials; Cross Infection; Disease Models, Animal; Drug Administration Schedule; Drug Interactions; Drug resistance; Drug Resistance, Multiple, Bacterial - physiology; Drug therapy; Gram-Positive Bacteria; Gram-positive bacterial infections; Health aspects; Human bacterial diseases; Humans; Infectious diseases; Internal Medicine; Medical sciences; Medicine; Medicine & Public Health; Methicillin - therapeutic use; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus - drug effects; Microbial polysaccharides; Microbial Sensitivity Tests; Miscellaneous; Oxacillin - administration & dosage; Pathogens; Pharmacodynamics; Pharmacokinetics; Pharmacology. Drug treatments; Pharmacology/Toxicology; Pharmacotherapy; Skin Diseases, Infectious; Staphylococcal Infections - drug therapy; Staphylococcus infections; Surveillance; Treatment Outcome; Vancomycin - administration & dosage; Vancomycin - therapeutic use
• ISSN: 0012-6667; 1179-1950
• DOI: 10.2165/10481380-000000000-00000

▴ Telavancin is the first available lipoglycopeptide antibacterial agent. It is active against Gram-positive bacteria, including meticillin/oxacillin-resistant Staphylococcus aureus (MRSA) strains associated with complicated skin and skin structure infections (cSSSIs). ▴ In randomized, double-blind trials, intravenous telavancin 10 mg/kg once daily (administered as a 1-hour infusion) was effective in the treatment of adult patients with cSSSIs, including those with infections caused by MRSA, as shown by clinical cure rates in clinically evaluable, all-treated and microbiologically evaluable populations at the test-of-cure (TOC) visit. ▴ Telavancin 10 mg/kg once daily was noninferior to intravenous vancomycin 1 g every 12 hours, with clinical cure rates of 88% versus 87% at the TOC visit in pooled data from the clinically evaluable population (n=1489) of two phase III trials. ▴ Pooled clinical cure rates in telavancin recipients at the TOC visit were also not significantly different from those in vancomycin recipients in the all-treated or microbiologically evaluable populations, including microbiologically evaluable subgroups with baseline infections caused by MRSA, meticillin-susceptible S. aureus or other Gram-positive pathogens. ▴ Telavancin was generally well tolerated in patients with cSSSIs, with most adverse events being of mild or moderate severity.